Combo

[Littlebiobet]

https://www.biopharmadive.com/news/bris ... halassemia.

Not sure if this was posted in the past. Small mention of imetelstat and possible combination with luspatercept.

Also BMS projects sales of $4 billion by 2030 for luspatercept. This is higher than imetelstats TAM with what seems to be an inferior drug for at least 75% of the patient population . That math doesn’t seem to math to me.

Anyone care to share any insight into this?

[Hoosier Investor]

It seems plausible they could be used in combination given the different MOAs and (likely) acceptable toxicity profile...especially for HR-MDS patients with few other treatment options. However, there's been no discussion of the combo to my knowledge, nor any pre-clinical data which would be a prerequisite to any clinical studies.

BMS (Luspatercept) is clearly going to lose market share to Imetelstat in the MDS space. Imetelstat seems to be the more potent/effective treatment of the two... albeit with more SAEs that Luspatercept. That's why some people/entities felt there was a chance the FDA would restrict Imetelstat usage to post-Luspatercept. However, we got a clean (broad) label from the FDA with no such restrictions. Thus, Imetelstat is clearly going to infringe on BMS market share... likely in a significant manner. Some of this will be out of choice (physician preference) and some will be necessary due to Luspatercept treatments not being effective.

Both of our patient speakers during the ODAC (March 14th) had tried Luspatercept before moving to Imetelstat. In both cases, the patients indicated little (to no) benefit from Luspatercept while Imetelstat restored their quality of life within a few months. Thus, at a minimum, there's a subset of patients who will benefit significantly from Imetelstat with minimal benefit from Luspatercept.

Thanks for the post and welcome to the forum.

[lausanne]

Not quite the same topic, but I found this comparison as per ChatGPT interesting: (Verbatim)


2. Indications:
Luspatercept (Reblozyl):
Approved for the treatment of anemia in adults with beta-thalassemia and MDS who require regular red blood cell transfusions.
Imetelstat (Raytelo):
Approved by the FDA for patients with high-risk myelodysplastic syndromes (MDS). Imetelstat is seen as a significant advancement in these areas due to its potential to alter the disease course and improve survival rates.
3. Safety and Warnings:
Luspatercept (Reblozyl):
Luspatercept carries a boxed warning due to the risks of severe cardiovascular events, including thrombosis and hypertension, requiring careful patient monitoring.
Imetelstat (Raytelo):
Imetelstat, in contrast, has no boxed warnings or severe label warnings. This favorable safety profile makes it a highly attractive option, especially given its efficacy in treating high-risk MDS and myelofibrosis.
4. Efficacy:
Luspatercept (Reblozyl):
Luspatercept has been shown to reduce the need for transfusions in patients with beta-thalassemia and MDS, improving quality of life for many patients.
Imetelstat (Raytelo):
Imetelstat has demonstrated superior efficacy in extending survival and reducing disease burden in patients with high-risk MDS and myelofibrosis. The drug's ability to induce complete or partial remissions in some patients marks it as a significant advance in hematology.
5. Side Effects:
Luspatercept (Reblozyl):
Common side effects include fatigue, dizziness, hypertension, and thromboembolic events, necessitating careful patient selection and monitoring.
Imetelstat (Raytelo):
While imetelstat is associated with some side effects like cytopenias and liver enzyme elevations, its overall safety profile is considered manageable, especially given its significant therapeutic benefits.
Conclusion:
Imetelstat (Raytelo) represents a major advancement in the treatment of high-risk MDS and myelofibrosis, with superior efficacy and a favorable safety profile compared to Luspatercept (Reblozyl). The absence of a boxed warning and its potential to modify the course of hematologic diseases make imetelstat a preferred option in its approved indications.

[Hoosier Investor]

Thanks for the ChatGPT summary.... very interesting. Interesting that it got our FDA approval incorrect (LR-MDS vs. HR-MDS). It also leveraged some of our P2 MF data to project the survival benefit (which is still under P3 study & review).

Personally, I haven't used ChatGPT yet. It seems a powerful tool that's going to improve (accuracy) with time.

If you're willing, I'd be curious to see a ChatGPT summary on the role/importance of inducing ferroptosis as a cancer treatment... solid tumors and/or blood (heme) cancer types. In our case, Imetelstat would be administered in combination with a chemotherapy treatment (NOTE: Azacitidine would be the combination chemo drug for MDS & AML blood cancers). Thanks in advance for any info/efforts!

[Hoosier Investor]

If you're willing, how about another search on the following...

"Telomere length (or telomerase expression) as a predictor of survival in Lymphoma (B-Cell or T-Cell)?"

[lausanne]

Here is what ChatGPT says:


Telomere length and telomerase expression have been studied extensively as potential biomarkers for prognosis in various cancers, including B-cell and T-cell lymphomas. Here’s an overview of how telomere length and telomerase activity can serve as predictors of survival in these types of lymphomas:

1. Telomere Length in Lymphoma:
General Role of Telomeres:
Telomeres are repetitive nucleotide sequences at the ends of chromosomes that protect them from degradation. As cells divide, telomeres progressively shorten, eventually leading to cellular senescence or apoptosis when they become critically short. In many cancers, including lymphomas, cells circumvent this limit through the activation of telomerase, an enzyme that extends telomeres, allowing for continued cell division and tumor growth.
Telomere Length as a Prognostic Marker:
B-Cell Lymphoma:
In B-cell lymphomas, studies have shown that shorter telomere lengths are often associated with more aggressive disease and poorer prognosis. For example, shorter telomeres have been correlated with higher-grade lymphomas, such as diffuse large B-cell lymphoma (DLBCL), compared to lower-grade lymphomas like follicular lymphoma. Patients with shorter telomeres generally have shorter overall survival and progression-free survival.
T-Cell Lymphoma:
Similarly, in T-cell lymphomas, shorter telomeres have been linked to a more aggressive disease course. In certain subtypes of T-cell lymphomas, such as peripheral T-cell lymphoma (PTCL), shorter telomeres are associated with advanced disease stages and worse survival outcomes.
2. Telomerase Expression in Lymphoma:
General Role of Telomerase:
Telomerase is an enzyme complex that adds telomeric repeats to the ends of chromosomes, thus counteracting telomere shortening. In most normal somatic cells, telomerase activity is low or absent. However, in many cancers, including lymphomas, telomerase activity is upregulated, allowing cancer cells to maintain telomere length and proliferate indefinitely.
Telomerase as a Prognostic Marker:
B-Cell Lymphoma:
High telomerase activity or expression of the catalytic subunit of telomerase, hTERT (human telomerase reverse transcriptase), has been associated with poor prognosis in B-cell lymphomas. Studies indicate that higher telomerase activity correlates with more aggressive disease, higher tumor grade, and reduced overall survival in patients with DLBCL and other high-grade B-cell lymphomas.
T-Cell Lymphoma:
In T-cell lymphomas, elevated telomerase activity has similarly been linked to worse outcomes. Increased hTERT expression in T-cell lymphoma patients is associated with advanced stages of the disease, higher proliferation rates, and lower survival rates.
3. Clinical Implications:
Prognostic Value:
Both telomere length and telomerase activity have potential prognostic value in lymphomas. Shorter telomeres and higher telomerase activity are generally indicative of more aggressive disease and worse clinical outcomes. These biomarkers can be used to stratify patients into different risk categories, potentially guiding treatment decisions.
Therapeutic Targeting:
Targeting telomerase activity has been explored as a therapeutic strategy in various cancers, including lymphomas. Inhibitors of telomerase, such as imetelstat, are being investigated for their potential to limit cancer cell proliferation by inducing telomere shortening and cellular senescence.
Conclusion:
Telomere length and telomerase expression are important biomarkers in B-cell and T-cell lymphomas, with shorter telomeres and higher telomerase activity generally associated with worse survival outcomes. These factors can be valuable in predicting disease progression and guiding therapeutic decisions, making them critical components of personalized medicine approaches in lymphoma treatment.

[lausanne]

Imetelstat's further query: (ChatGPT)

Imetelstat is directly related to the discussion of telomere length and telomerase expression as prognostic factors in cancers like lymphoma. Here’s how imetelstat comes into play:

1. Imetelstat’s Mechanism of Action:
Telomerase Inhibition:
Imetelstat is a first-in-class telomerase inhibitor. It works by binding to the RNA template of telomerase (hTERC), thereby preventing the enzyme from adding telomeric repeats to the ends of chromosomes. This inhibition leads to progressive telomere shortening in dividing cancer cells, ultimately causing cellular senescence or apoptosis.
2. Application in Hematologic Malignancies:
Targeting Telomerase-Positive Cells:
In hematologic malignancies like certain types of myelodysplastic syndromes (MDS) and myelofibrosis, where telomerase activity is upregulated, imetelstat has shown efficacy in clinical trials. By inhibiting telomerase, imetelstat reduces the proliferative capacity of malignant cells, which can lead to disease modification and potentially improved survival outcomes.
Lymphoma Context:
While imetelstat has primarily been studied in MDS and myelofibrosis, its mechanism of targeting telomerase is highly relevant to B-cell and T-cell lymphomas as well. Given that shorter telomere length and higher telomerase activity are associated with more aggressive lymphoma and worse prognosis, inhibiting telomerase with imetelstat could theoretically reduce the survival advantage of lymphoma cells, slowing disease progression.
3. Potential Role of Imetelstat in Lymphoma Treatment:
Therapeutic Potential:
Although imetelstat is not yet widely studied or approved for the treatment of lymphomas, its action against telomerase makes it a promising candidate for future research in this area. By inhibiting telomerase, imetelstat could potentially:
Reduce the proliferation of telomerase-positive lymphoma cells.
Induce telomere shortening in these cells, leading to cell death or senescence.
Modify the course of aggressive lymphomas that are dependent on telomerase for continued growth.
Rationale for Further Research:
Given the strong link between telomerase activity and poor prognosis in lymphomas, there is a clear rationale for investigating imetelstat as a treatment option. If proven effective, imetelstat could become part of the therapeutic arsenal for treating high-risk lymphomas with high telomerase expression.
4. Clinical Implications:
Personalized Medicine:
If imetelstat were to be applied to lymphoma treatment, it could be particularly beneficial for patients with high telomerase activity or shorter telomeres, as these patients typically have more aggressive disease and poorer outcomes. Telomerase inhibition could help to improve survival and reduce disease progression in these high-risk groups.
Combination Therapies:
Imetelstat might also be explored in combination with other therapies to enhance its efficacy. For example, combining it with chemotherapy, immune checkpoint inhibitors, or other targeted therapies could provide a synergistic effect, further improving outcomes for lymphoma patients.
Conclusion:
Imetelstat’s role as a telomerase inhibitor makes it a highly relevant therapeutic option in the context of lymphomas characterized by high telomerase activity and poor prognosis. While primarily studied in other hematologic malignancies, the potential application of imetelstat in treating B-cell and T-cell lymphomas presents an exciting avenue for future research, offering hope for more effective treatments in aggressive cases.